Bethlehem: Piramal Critical Care (PCC), a division of Piramal Pharma Limited, has announced the launch of a new 10mg/10mL (1 mg/mL) concentration of Zinc Sulfate for Injection USP in the U.S. The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio. Zinc Sulfate is a trace element indicated in adult...
Bethlehem: Piramal Critical Care (PCC), a division of Piramal Pharma Limited, has announced the launch of a new 10mg/10mL (1 mg/mL) concentration of Zinc Sulfate for Injection USP in the U.S.
The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio. Zinc Sulfate is a trace element indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. This intravenous nutritional injection is available in three strengths: 30mg/10mL (3mg/mL), 25mg/5mL (5mg/mL), and the new 10mg/10mL (1mg/mL) concentration. The 1 mg/mL concentration is recommended for use in pediatric patients, particularly those weighing less than 26 pounds.
Peter DeYoung, Chief Executive Officer of Piramal Global Pharma commented, “Piramal Critical Care (PCC) is excited to introduce the latest addition to our lineup: the 10mg/10mL (1 mg/mL) concentration of Zinc Sulfate for Injection. This launch aligns with our core mission of supplying the market with medications that play a crucial role in saving and enhancing patients' lives. The introduction of Zinc Sulfate Injection expands our US portfolio of injectable products, complementing our already market-leading inhaled anesthesia offerings. Our commitment to delivering critical care solutions remains steadfast as we aim to serve patients and healthcare providers, in the U.S. and globally.”
The launch of Zinc Sulfate for Injection, USP 10mg/10ml is the latest in a series of recent product launches from Piramal Critical Care in the generic injectables market.
In 2023, Piramal Critical Care also announced launches of Pantoprazole Sodium for Injection, USP and Doxycycline for Injection, USP to further complement their wide portfolio of critical care products.
Piramal Critical Care maintains a wide global footprint, delivering continuous supply to hospitals in more than 100 countries around the world. Their product portfolio includes inhaled anesthetics, intrathecal treatments for spasticity and pain management, plasma volume expanders, and a variety of other injectables and generics. Piramal Critical Care has manufacturing and process development capabilities with state-of-the-art manufacturing facilities in Bethlehem, PA, United States, Digwal, India, and Dahej, India with global regulatory accreditations and adherence to strict GMP regulations.
Read also: Piramal Pharma Solutions unveils in-vitro biology capabilities at Ahmedabad Discovery Services Site
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd